Equities analysts expect that Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will post $4.43 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Arena Pharmaceuticals’ earnings. The highest sales estimate is $4.86 million and the lowest is $4.00 million. Arena Pharmaceuticals reported sales of $85.37 million during the same quarter last year, which indicates a negative year-over-year growth rate of 94.8%. The firm is scheduled to issue its next earnings report on Tuesday, March 13th.
On average, analysts expect that Arena Pharmaceuticals will report full-year sales of $4.43 million for the current financial year, with estimates ranging from $25.10 million to $30.00 million. For the next fiscal year, analysts expect that the firm will report sales of $24.11 million per share, with estimates ranging from $18.00 million to $28.33 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Arena Pharmaceuticals.
Arena Pharmaceuticals (NASDAQ:ARNA) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.66) by $0.01. Arena Pharmaceuticals had a negative return on equity of 34.12% and a negative net margin of 36.78%. The firm had revenue of $7.95 million during the quarter, compared to analyst estimates of $5.48 million. During the same period last year, the company earned ($0.05) EPS. Arena Pharmaceuticals’s quarterly revenue was down 58.6% compared to the same quarter last year.
Institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new stake in Arena Pharmaceuticals during the 3rd quarter valued at about $9,973,000. American Century Companies Inc. grew its stake in Arena Pharmaceuticals by 171.8% during the 3rd quarter. American Century Companies Inc. now owns 64,994 shares of the biopharmaceutical company’s stock valued at $1,657,000 after purchasing an additional 41,082 shares during the last quarter. Swiss National Bank grew its stake in Arena Pharmaceuticals by 30.3% during the 3rd quarter. Swiss National Bank now owns 63,630 shares of the biopharmaceutical company’s stock valued at $1,623,000 after purchasing an additional 14,800 shares during the last quarter. ClariVest Asset Management LLC purchased a new stake in Arena Pharmaceuticals during the 3rd quarter valued at about $2,156,000. Finally, Nationwide Fund Advisors grew its stake in Arena Pharmaceuticals by 109.0% during the 3rd quarter. Nationwide Fund Advisors now owns 38,751 shares of the biopharmaceutical company’s stock valued at $988,000 after purchasing an additional 20,209 shares during the last quarter. Institutional investors and hedge funds own 72.82% of the company’s stock.
Shares of Arena Pharmaceuticals (NASDAQ:ARNA) traded down $2.44 during midday trading on Tuesday, reaching $38.40. The company’s stock had a trading volume of 829,800 shares, compared to its average volume of 930,900. The company has a current ratio of 4.42, a quick ratio of 4.32 and a debt-to-equity ratio of 0.27. The company has a market cap of $1,510.00, a price-to-earnings ratio of -40.85 and a beta of 1.49. Arena Pharmaceuticals has a 1-year low of $11.30 and a 1-year high of $41.92.
TRADEMARK VIOLATION WARNING: “$4.43 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter” was originally published by BBNS and is the property of of BBNS. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/4-43-million-in-sales-expected-for-arena-pharmaceuticals-inc-arna-this-quarter/1820573.html.
Arena Pharmaceuticals Company Profile
Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.